Eyepoint Duravyu misses Phase 3 goal, stock plunges
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eyepoint said Monday its Phase 3 trial of Duravyu for wet age-related macular degeneration (wet AMD) missed its primary goal: patients failed to maintain vision with less frequent injections compared to the current standard of care.
- Duravyu's regulatory path is now uncertain, as the trial setback imperiled Eyepoint's plans to seek FDA approval for the drug.
- Eyepoint's stock price plummeted following the announcement of the disappointing trial results.
- Ocular Therapeutix, developer of a competing wet AMD treatment, saw its shares rise on the news; the company plans to submit its own drug to the FDA later this year.
- Both Eyepoint and Ocular Therapeutix are pursuing drugs that could reduce the injection burden for wet AMD patients compared to currently approved treatments.
Why it matters: A failed Phase 3 in wet AMD reshapes the competitive landscape: Ocular Therapeutix's rival treatment now appears better positioned for FDA submission later this year, while Eyepoint faces an uncertain regulatory path and a sharp stock decline, leaving patients waiting for a less-frequent-injection wet AMD therapy with fewer near-term options.
Ask SkimNews
